On Tuesday, Shares of Ocwen Financial Corp (NYSE:OCN), subtract -3.57% and closed at $3.51 in the last trading session. The last trading range of the stock ranges between $3.48 and $3.79. The company’s Market capitalization is $423.56 million with the total Outstanding Shares of 123.99 million. During the 52-week trading session the minimum price at which share price traded, registered at $1.29 and reached to max level of $8.34. Ocwen Financial Corporation (OCN), a leading financial services holding company, and NID Housing Counseling Agency (NID), a U.S. Department of Housing and Urban Development (HUD)-approved counseling organization headquartered in Oakland, CA, will host a borrower outreach event on Saturday, October 8, 2016 in Sacramento, California. The Sacramento Chapter of NAACP is teaming up with Ocwen and NID for this event to ensure a strong turnout of Ocwen customers.
The event will be held from 8:00 a.m. 2:00 p.m. at 2863 35th Street in Sacramento, across from Guild Theater. Admission and parking are free for all attendees. RSVPs are not required.
Ocwen customers, who are struggling to meet their mortgage obligations, will have the opportunity to meet one-on-one with Ocwen Home Retention Agents and NID housing counselors to discuss loan modification options that could assist lower their mortgage payments.
“Ocwen understands that many Californians continue to struggle financially, have questions about their mortgages, and want to explore options to better afford their homes,” said Jill Showell, Senior Vice President of Government and Community Relations at Ocwen. “Our experience has shown that face-to-face meetings often provide the best forum for borrowers to fully understand what options are available. We are proud to be working with NID and the NAACP to bring responsible solutions to as many struggling borrowers as possible.”
NXP Semiconductors NV (NASDAQ:NXPI), dropped -0.88% and closed at $101.93 in the last trading session. The last trading range of the stock ranges between $100.69 and $102.77. During the 52-week trading session the minimum price at which share price traded, registered at $61.61 and reached to max level of $105.29. NXP Semiconductors N.V. (NXPI) recently declared it will release financial results for the third quarter of 2016 after the close of extended trading on the NASDAQ Global Select Market on Wednesday, October 26, 2016. The release will be followed by a conference call with the financial community on Thursday, October 27, 2016 at 8:00 a.m. U.S. Eastern Daylight Time (EDT).
NXP Semiconductors N.V. (NXPI) facilitates secure connections and infrastructure for a smarter world, advancing solutions that make lives easier, better and safer. As the world leader in secure connectivity solutions for embedded applications, NXP is driving innovation in the secure connected vehicle, end-to-end security & privacy and smart connected solutions markets.
On the otherhand Northwest Biotherapeutics, Inc (NASDAQ:NWBO), gained 8.15% and closed at $0.495 in the last trading session. The last trading range of the stock ranges between $0.46 and $0.57. The company’s Market capitalization is $61.07 billion with the total Outstanding Shares of 113.74 million. During the 52-week trading session the minimum price at which share price traded, registered at $0.32 and reached to max level of $6.26. Northwest Biotherapeutics (NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, declared that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, presented additional information regardingthe DCVax®-Direct Phase I Trial in a poster presentation at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held from September 25th through September 28th in New York City.
Dr. Bosch’s New York presentation, in addition to his presentation at a cancer vaccines conference in London last week, included information about estimated life expectancies for individual patients (not for types of cancers or medians of groups of patients) based on a system developed and published by Dr. Jennifer Wheler at MD Anderson Cancer Center. The Wheler system was based upon clinical experience with 1,181 patients with diverse cancers at the MD Anderson Phase I Cancer Clinic (where most of the DCVax-Direct Trial was conducted). Wheler validated and improved (with additional risk factors) a system for prediction of individual-patient life expectancies formerly developed by the Royal Marsden Hospital in the UK and well established in the field.
A fundamental purpose of early stage exploratory trials, such as the DCVax-Direct Phase I trial, is to evaluate both product characteristics and patient characteristics – and especially to identify which patients show the best responses to the experimental product. Such evaluations facilitate later stage trials to be designed with more precision, to focus on the patients who are the best fit for the experimental product and to potentially best demonstrate the performance of the experimental product.